Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters

Stanley Druckenmiller's latest 13F filings reveal a significant portfolio reallocation, notably the complete divestment of Palantir Technologies (PLTR) due to concerns over its extreme valuation (P/S 119) and potential AI overhype, despite substantial prior gains. Concurrently, Duquesne Family Office aggressively built positions in Teva Pharmaceutical Industries (TEVA) for three consecutive quarters, citing resolved litigation, a strategic shift to novel drugs, an improved balance sheet, and an attractive 5.8x forward P/E. Druckenmiller also consistently increased his stake in Taiwan Semiconductor Manufacturing (TSM), recognizing its critical role in AI chip fabrication while valuing its diversified revenue streams beyond AI and a reasonable forward P/E of under 22, positioning it as a more resilient AI play.

Analysis

Recent 13F filings from Duquesne Family Office indicate a significant strategic shift by Stanley Druckenmiller, highlighted by the complete divestment of his fund's position in Palantir Technologies (PLTR). This move appears driven by more than simple profit-taking on the stock's over 2,200% gain since 2023; it reflects a broader concern about a short-term bubble in the artificial intelligence sector. Palantir's valuation, at a price-to-sales ratio of nearly 119, is cited as historically unsustainable when compared to the 31-43 P/S peaks seen during the dot-com era, signaling a high risk of mean reversion. Concurrently, Druckenmiller has aggressively increased his stakes in two other companies for the third consecutive quarter. The fund's position in Teva Pharmaceutical Industries (TEVA) has grown to become its second-largest holding, driven by a clear turnaround thesis: the resolution of major opioid litigation for a manageable $4.25 billion over 13 years, a strategic pivot towards higher-margin novel drugs, and significant balance sheet improvement with net debt reduced from over $35 billion to under $15 billion. Teva's valuation, at a forward P/E of 5.8, presents a stark contrast to Palantir. Similarly, the fund has consistently added to its Taiwan Semiconductor Manufacturing (TSM) holdings, positioning it as a more fundamentally-grounded AI play. TSM's critical role in the AI supply chain is complemented by diversified revenue from non-AI segments like smartphones and automotive, providing a buffer against a potential AI sector downturn. Its forward P/E of less than 22 is deemed reasonable given its projected sales growth of 26% in 2025.

Key Decisions for Investors

• Investors in Palantir should critically assess its current valuation, as a prominent manager's exit based on a P/S ratio of 119 and concerns of an AI bubble suggests significant downside risk.
• Consider Teva Pharmaceutical as a potential value and turnaround opportunity, given its resolved litigation overhang, deleveraged balance sheet, strategic shift to novel drugs, and a highly attractive forward P/E of 5.8.
• For exposure to the AI secular trend with a more defensive positioning, Taiwan Semiconductor offers a compelling alternative due to its essential role in the supply chain, diversified end markets, and a more reasonable valuation relative to its growth prospects.
• The stark contrast in these portfolio moves suggests a potential rotation from high-multiple, speculative AI names towards value and mission-critical infrastructure, a theme that warrants monitoring for broader market shifts.